Primary systemic amyloidosis
MONDO:0017816Primary systemic amyloidosis (PSA) is a form of AL amyloidosis caused by the aggregation and deposition of insoluble amyloid fibrils derived from misfolded monoclonal immunoglobulin light chains usually produced by a plasma cell tumor and characterized by multiple organ involvement.
Also known as: systemic AL amyloidosis, systemic Immunoglobulin Light chain amyloidosis, systemic amyloidosis
30 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
Engineered immune cells take aim at a rare Protein-Folding disease
⭐️ CURE ⭐️ Not yet recruitingThis trial is testing an experimental treatment called FKC289 for people with primary AL amyloidosis that has relapsed or not responded to standard care. FKC289 uses a patient's own immune cells, engineered to recognize and attack the abnormal plasma cells that produce the harmfu…
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Fosun Kairos Biotechnology Co., Ltd. • Aim: ⭐️ CURE ⭐️
Last updated Aug 16, 2026 00:00 UTC
-
New scan spots hidden organ damage before symptoms start
Diagnosis Not yet recruitingThis study explores whether a PET/MR scan using a radioactive tracer called 18F-Florbetaben can detect amyloid deposits—abnormal protein clumps that can damage organs—in people with certain blood disorders. Participants receive a single injection of the tracer followed by a whole…
Phase: NA • Sponsor: University of Zurich • Aim: Diagnosis
Last updated Jun 27, 2026 13:00 UTC